AHA 2018

Here you will find the highlights of the AHA 2018, held on November 10-12 in the city of Chicago, USA.

Disminuye la profilaxis de endocarditis luego de las guías del 2007

AHA 2018 | Endocarditis Prophylaxis More Limited after AHA 2007 Guidelines
The incidence of infective endocarditis had decreased after AHA 2007 recommendations. At present, some patients are not receiving antibiotic prophylaxis as they should. After AHA ...

AHA 2018 | DES de última generación similares a los de 2° generación más allá del polímero

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer
Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting stents with durable polymer such as ...

AHA 2018 | El dispositivo Impella gana evidencia, pero hacen faltan estudios más grandes

AHA 2018 | More Evidence for the Impella Device, But Larger Trials Are Necessary
In this pilot study, unloading the left ventricle with the Impella CP circulatory support device and delaying angioplasty by about 30 minutes appeared to be feasible and safe in patients with ...

AHA 2018 | Safenectomía endoscópica en pacientes para cirugía de revascularización miocárdica

AHA 2018 | Endoscopic Saphenous-Vein-Graft Harvesting in Patients Undergoing Myocardial Revascularization Surgery
For patients undergoing myocardial revascularization surgery, endoscopic harvesting of saphenous veins in expert hands is similar to traditional methods in terms of events, according to this study ...

Nuevas guías de actividad física ponen en movimiento a todas las edades

AHA 2018 | New Physical Activity Guidelines Recommend Movement for All Ages
The new 2018 physical activity guidelines continue to recommend the same amount of physical activity (300 minutes of moderate-intensity physical activity per week or 150 minutes of ...

AHA 2018 | Utilidad del balón de contrapulsación según el IABP-SHOCK II trial

AHA 2018 | Use of Balloon Counterpulsation According to IABP-SHOCK II Trial
Following up on the 30 day and one year effect, the IABP-SHOCK II trial long term outcomes showed there is not benefit to the use of intraaortic balloon counterpulsation in cardiogenic shock ...

AHA 2018 | Seguimiento a largo plazo del Freedom: se mantiene el beneficio a favor de la cirugía

AHA 2018 | Freedom Long-Term Follow-up: Still in Favor of CABG
Nearly 8 years later, CABG maintains its benefit over PCI-DES in terms of mortality in diabetic patients with multivessel disease, according to the Freedom trial, presented by Dr. Fuster at AHA and ...

AHA 2018 | PIONEER-HF: sacubitril/valsartan en insuficiencia cardíaca aguda descompensada

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure
Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly reduces N-terminal pro-B-type natriuretic peptide ...

Las nuevas guías de dislipemia apoyan la terapia sin estatinas y la búsqueda de calcio coronario

AHA 2018 | New Dyslipidemia Guidelines Support Non-Statin Therapy and Coronary Artery Calcium Screening
While the guidelines do not recommend a specific treatment target, they suggest additional therapy in high-risk patients with LDL 70 mg/dL or higher. These new guidelines from the American ...

AHA 2018 | El metotrexate como anti inflamatorio no logró mostrar beneficios

AHA 2018 | No Benefits with Methothrexate as Anti-Inflammatory Drug
Low-dose methotrexate (a nonspecific anti-inflammatory agent used for the treatment of rheumatoid arthritis and other autoimmune disorders) did not prevent cardiovascular events in patients with a ...

El Canakinumab reduce las hospitalizaciones por insuficiencia cardíaca en los respondedores

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents
The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior MI and hypersensitivity C-reactive protein (hsCRP) showed dose ...